JP2004520423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520423A5 JP2004520423A5 JP2002569799A JP2002569799A JP2004520423A5 JP 2004520423 A5 JP2004520423 A5 JP 2004520423A5 JP 2002569799 A JP2002569799 A JP 2002569799A JP 2002569799 A JP2002569799 A JP 2002569799A JP 2004520423 A5 JP2004520423 A5 JP 2004520423A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- phenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- -1 nitro, hydroxy Chemical group 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 description 28
- 208000006673 asthma Diseases 0.000 description 12
- 201000004624 Dermatitis Diseases 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 206010024229 Leprosy Diseases 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010011416 Croup infectious Diseases 0.000 description 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000027445 Farmer Lung Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- 208000036284 Rhinitis seasonal Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 201000010549 croup Diseases 0.000 description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 206010035653 pneumoconiosis Diseases 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000001319 vasomotor rhinitis Diseases 0.000 description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 2
- 0 *C(C(*)(C(*)(*=*)N)*=*)N(CC1)CCC1N(*)C(*)=O Chemical compound *C(C(*)(C(*)(*=*)N)*=*)N(CC1)CCC1N(*)C(*)=O 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0105077A GB0105077D0 (en) | 2001-03-01 | 2001-03-01 | Chemical Compounds |
| GB0115579A GB0115579D0 (en) | 2001-06-26 | 2001-06-26 | Chemical compounds |
| SE0103797A SE0103797D0 (sv) | 2001-11-13 | 2001-11-13 | Chemical compounds |
| PCT/SE2002/000351 WO2002070479A1 (en) | 2001-03-01 | 2002-02-27 | N-4-piperidinyl compounds as ccr5 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520423A JP2004520423A (ja) | 2004-07-08 |
| JP2004520423A5 true JP2004520423A5 (https=) | 2006-01-05 |
Family
ID=27256088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569799A Pending JP2004520423A (ja) | 2001-03-01 | 2002-02-27 | Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20040110952A1 (https=) |
| EP (1) | EP1368314A1 (https=) |
| JP (1) | JP2004520423A (https=) |
| WO (1) | WO2002070479A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| SE0200919D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
| SE0202483D0 (sv) * | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| SE0301369D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| EP1786816A4 (en) | 2003-09-10 | 2009-11-04 | Virochem Pharma Inc | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY |
| SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| TW200815353A (en) | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| CN101412692B (zh) * | 2007-10-18 | 2012-10-17 | 中国科学院上海药物研究所 | 1-(3-氨基丙基)哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途 |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| CN108884026B (zh) | 2016-03-22 | 2021-05-25 | 赫尔森保健股份公司 | 苯磺酰基不对称尿素及其医学用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| WO2000076513A1 (en) * | 1999-06-11 | 2000-12-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-02-27 WO PCT/SE2002/000351 patent/WO2002070479A1/en not_active Ceased
- 2002-02-27 US US10/469,361 patent/US20040110952A1/en not_active Abandoned
- 2002-02-27 EP EP02700965A patent/EP1368314A1/en not_active Withdrawn
- 2002-02-27 JP JP2002569799A patent/JP2004520423A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520423A5 (https=) | ||
| JP4669836B2 (ja) | ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途 | |
| JP2003507456A5 (https=) | ||
| ES2795366T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
| US9193719B2 (en) | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP5085659B2 (ja) | Ｌ−ｃｐｔ１阻害剤として有用なインダゾール誘導体 | |
| JP2020537657A5 (https=) | ||
| JP2005503394A5 (https=) | ||
| JP2020528889A5 (https=) | ||
| JP6276760B2 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| JP2018519323A5 (https=) | ||
| JP2004504301A5 (https=) | ||
| SK16152002A3 (sk) | Farmacueticky účinné piperidínové deriváty, najmä ako modulátory aktivity chemokínového receptora | |
| JP2005509622A5 (https=) | ||
| JP2009524691A5 (https=) | ||
| JP2009534421A5 (https=) | ||
| JP2004506718A5 (https=) | ||
| RU98123097A (ru) | Карбоксамиды бензофурана и их терапевтическое применение | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| JP2014520809A5 (https=) | ||
| BR112016011065B1 (pt) | Composto cristalino e seu uso, composição farmacêutica e seu uso, forma de dosagem, método para preparar um composto | |
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| JP2007501831A5 (https=) | ||
| CA2575777A1 (en) | Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives | |
| JP2007519742A5 (https=) |